
---
title: '国金证券：关注下半年医药政策边际利好趋势'
categories: 
 - 金融
 - 证券时报网
 - 快讯
headimg: 'https://picsum.photos/400/300?random=4075'
author: 证券时报网
comments: false
date: Tue, 14 Jun 2022 08:32:00 GMT
thumbnail: 'https://picsum.photos/400/300?random=4075'
---

<div>   
<p>证券时报网讯，<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS600109" code="600109">国金证券</a>指出，国内外生物医药指数出现触底回升趋势，建议关注下半年医药政策边际利好趋势，持续看好差异化创新和创新出海。建议关注：<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS688331" code="688331">荣昌生物</a>、金斯瑞生物科技、信达生物、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS600276" code="600276">恒瑞医药</a>、科济药业等。 </p>

                  
</div>
            